Drug Eluting Balloon - A Breakthrough in Treating Peripheral Artery Disease
 |
| Drug Eluting Balloon |
What
are Drug Eluting Balloons?
Drug-eluting balloons (DEBs) are angioplasty balloons coated with an anti-proliferative
drug, typically paclitaxel, dexamethasone, or sirolimus. During angioplasty to
open blocked arteries, the drug-coated balloon is inflated at the site of
stenosis to deliver the drug directly to the vessel wall. This helps prevent
restenosis or re-narrowing of the artery which commonly occurs with
conventional balloon angioplasty and bare metal stenting.
Drugs used in DEBs
The most commonly used drug is paclitaxel, a chemotherapy drug that works by
preventing cell division and proliferation. When delivered locally via a Drug
Eluting Balloon, it inhibits neointimal hyperplasia which is the
narrowing of the artery that occurs after conventional angioplasty as the body
tries to repair the damaged vessel wall. This helps maintain vessel patency for
a longer period.
Dexamethasone, a corticosteroid, works by modulating the body's immune response
and reducing inflammation at the treatment site. Sirolimus, also called
rapamycin, is an immunosuppressive drug that prevents proliferation of smooth
muscle cells in the vessel wall. All three drugs help address restenosis by
limiting cell overgrowth post angioplasty.
Advantages over Other Treatments
Compared to plain old balloon angioplasty (POBA) which has high restenosis
rates of 30-50%, drug-eluting balloons significantly reduce the risk of
re-narrowing when used for indications like superficial femoral artery disease.
They also appear superior to drug-eluting stents in preventing instent
restenosis for below-the-knee interventions.
Unlike stents, DEBs do not introduce a permanent foreign body into the vessel.
This eliminates issues like late stent thrombosis seen with drug-eluting
stents. DEBs also have advantages over uncoated balloons like betterlesion
crossing ability and pushability.
Areas of Application
Given their proven benefits, drug-eluting balloons are increasingly being used
for endovascular treatment of peripheral artery disease (PAD) involving the
superficial femoral artery (SFA), popliteal artery and below-the-knee vessels
like tibial and peroneal arteries. Restenosis following angioplasty remains a
challenge in smaller vessels below the knee. DEBs overcome this limitation and
offer patients an alternative to repeat revascularization procedures or
amputation.
Drug-eluting balloons are also used for in-stent restenosis where a previously
placed stent gets blocked again. By delivering high drug doses locally, DEBs
can re-treat such lesions more effectively than plain balloon angioplasty.
Overall, DEBs expand the scope of endovascular therapy to more complex PAD
cases including complex long lesions, chronic total occlusions, small vessel
and instent restenosis scenarios.
Clinical Evidence
Several randomized controlled trials have validated the benefits of DEBs. The
landmark IN.PACT SFA trial compared standard angioplasty to treatment with a
paclitaxel-coated balloon (IN.PACT Admiral) for SFA disease. It found that DEB
angioplasty significantly reduced rates ofrestenosis and target lesion
revascularization over 12 months.
The FEMPac trial also looked at outcomes with DEBs in SFA. At 24 months
follow-up, patients who received a paclitaxel balloon had much lower rates of
re-intervention compared to those treated with an uncoated balloon.
Other studies like the THUNDER trial proved the safety and efficacy of DEBs for
treating small vessel PAD like below-the-knee arteries with good mid-term
patency outcomes. In stent restenosis was effectively addressed in trials like
IN.PACT SFA drug-coated balloon versus standard angioplasty for the treatment
of SFA In-Stent restenosis.
Overall, there is a robust body of Level 1 evidence from randomized studies
establishing drug-eluting balloons as a primary option for endovascular
revasvularization in suitable patients with PAD. They deliver significant
advantages over uncoated balloons or drug-eluting stents.
Safety Considerations
While they are generally safe and well-tolerated, there are some potential concerns
due to the drug coatings:
- Allergic reactions to the drugs used, especially paclitaxel, are possible in
sensitive patients. Skin testing may be done prior to treatment.
- Systemic drug absorption into bloodstream with toxic effects cannot be entirely
ruled out. However levels are expected to be very low.
- Long term safety profile is still under evaluation as DEBs are a relatively
new technology. Large registry data will provide more definitive answers.
- Cost is currently higher than uncoated balloons but may reduce with wider
adoption.
When handled properly as per manufacturer instructions by experienced
endovascular teams, they have an excellent safety profile. But like all new
devices, long term follow up is important to establish lifetime performance and
safety.
Advancements continue in this technology. Researchers are working on improving
drug coatings for enhanced drug transfer and modulated drug release properties.
Biodegradable polymer coatings that do not require drug diffusion are being
evaluated. Combination drug regimens may further reduce restenosis. Device
modifications such as drug-coated balloons with nanocoating technology hold
promise.
Developing patient-specific solutions based on individual lesion
characteristics will optimize outcomes. Extending the benefits of DEB
angioplasty to coronary interventions is another active area of research.
Overall, drug-eluting balloons represent a major breakthrough in interventional
cardiology and vascular medicine. With continued developments, they have the
potential to transform endovascular therapy for PAD and other vascular
conditions globally.
About Author:
Vaagisha brings over three
years of expertise as a content editor in the market research domain.
Originally a creative writer, she discovered her passion for editing, combining
her flair for writing with a meticulous eye for detail. Her ability to craft
and refine compelling content makes her an invaluable asset in delivering
polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
Comments
Post a Comment